Protective immune responses in mice induced by intramuscular and intranasal immunization with a Mycoplasma pneumoniae P1C DNA vaccine

Canadian Journal of Microbiology

Volumn 58, Issue 5, 2012, Pages 644-652

  Zhu, Cuiming ^a,b   Wu, Yimou ^b   Chen, Sufang ^b   Yu, Minjun ^b   Zeng, Yanhua ^b   You, Xiaoxing ^b   Xiao, Jinhong ^b   Wang, Shiping ^a  

^a Central South University   (China)

^b UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

DNA vaccine; Immune response; Mycoplasma pneumoniae; P1 adhesin protein carboxy terminal region

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 4; PHOSPHATE BUFFERED SALINE; PNEUMOCOCCUS VACCINE;

ANTIBODY; BACTERIUM; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; PNEUMONIA; PROTEIN; RODENT; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOUSE; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ADHESINS, BACTERIAL; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CELL PROLIFERATION; HELA CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; INTERLEUKIN-4; LUNG; MICE; MICE, INBRED BALB C; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; SPLEEN; VACCINES, DNA;

MUS; MYCOPLASMA PNEUMONIAE;

EID: 84860438806     PISSN: 00084166     EISSN: 14803275     Source Type: Journal    
DOI: 10.1139/W2012-041     Document Type: Article

References (38)

1. Barile, M.F., Chandler, D.K., Yoshida, H., Grabowski, M.W., and Razin, S. 1988a. Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines. Infect. Immun. 56(9): 2450-2457.
2. Barile, M.F., Chandler, D.K., Yoshida, H., Grabowski, M.W., Harasawa, R., and Razin, S. 1988b. Parameters of Mycoplasma pneumoniae infection in the Syrian hamster. Infect. Immun. 56(9): 2443-2449.
3. Baseman, J.B., Cole, R.M., Krause, D.C., and Leith, D.K. 1982. Molecular basis for cytadsorption of Mycoplasma pneumoniae. J. Bacteriol. 151(3): 1514-1522.
4. Boyle, J.S., Silva, A., Brady, J.L., and Lew, A.M. 1997. DNA immunization: induction of higher avidity antibody and effect of route on T cell cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 94(26): 14626-14631. doi:10.1073/pnas.94.26.14626.
5. Brown, R.C., Hendley, J.O., and Gwaltney, J.M., Jr. 1972. Mycoplasma pneumoniae vaccine: antigenicity of buffered antigens in volunteers. Infect. Immun. 5(5): 657-661.
6. Cassataro, J., Velikovsky, C.A., Giambartolomei, G.H., Estein, S., Bruno, L., Cloeckaert, A., et al. 2002. Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA. Vaccine, 20(11-12): 1660-1669. doi:10.1016/S0264-410X(01)00498-4.
7. Chaudhry, R., Nisar, N., Hora, B., Chirasani, S.R., and Malhotra, P. 2005. Expression and immunological characterization of the carboxy-terminal region of the P1 adhesin protein of Mycoplasma pneumoniae. J. Clin. Microbiol. 43(1): 321-325. doi:10.1128/JCM.43.1.321-325.2005.
8. Cimolai, N., Taylor, G.P., Mah, D., and Morrison, B.J. 1992. Definition and application of a histopathological scoring scheme for an animal model of acute Mycoplasma pneumoniae pulmonary infection. Microbiol. Immunol. 36(5): 465-478.
9. Cimolai, N., Cheong, A.C., Morrison, B.J., and Taylor, G.P. 1996. Mycoplasma pneumoniae reinfection and vaccination: protective oral vaccination and harmful immunoreactivity after re-infection and parenteral immunization. Vaccine, 14(15): 1479-1483. doi:10.1016/S0264-410X(96)00068-0.
10. Couch, R.B., Cate, T.R., and Chanock, R.M. 1964. Infection with artificially propagated Eaton agent (Mycoplasma pneumoniae): implications for development of attenuated vaccine for cold agglutinin-positive pneumonia. JAMA, 187(6): 442-447. doi:10.1001/jama.1964.03060190058015.
11. Dallo, S.F., Su, C.J., Horton, J.R., and Baseman, J.B. 1988. Identification of P1 gene domain containing epitope(s) mediating Mycoplasma pneumoniae cytoadherence. J. Exp. Med. 167(2): 718-723. doi:10.1084/jem.167.2.718.
12. Dobbs, N.A., Odeh, A.N., Sun, X., and Simecka, J.W. 2009. The multifaceted role of T cell-mediated immunity in pathogenesis and resistance to mycoplasma respiratory disease. Curr. Trends Immunol. 10: 1-19.
13. Dumke, R., Schurwanz, N., and Jacobs, E. 2008. Characterisation of subtype- and variant-specific antigen regions of the P1 adhesin of Mycoplasma pneumoniae. Int. J. Med. Microbiol. 298(5-6): 483-491. doi:10.1016/j.ijmm.2007.06.002.
14. Fernald, G.W., and Clyde, W.A. 1970. Protective effect of vaccines in experimental Mycoplasma pneumoniae disease. Infect. Immun. 1 (6): 559-565.
15. Greenberg, H., Helms, C.M., Grizzard, M.B., James, W.D., Horswood, R.L., and Chanock, R.M. 1977. Immunoprophylaxis of experimental Mycoplasma pneumoniae disease: effect of route of administration on the immunogenicity and protective effect of inactivated M. pneumoniae vaccine. Infect. Immun. 16(1): 88-92.
16. Gurunathan, S., Klinman, D.M., and Seder, R.A. 2000. DNA vaccines: immunology, application and optimization. Annu. Rev. Immunol. 18(1): 927-974. doi:10.1146/annurev.immunol.18.1.927.
17. Hu, P.C., Collier, A.M., and Baseman, J.B. 1977. Surface parasitism by Mycoplasma pneumoniae in respiratory epithelium. J. Exp. Med. 145(5): 1328-1343. doi:10.1084/jem.145.5.1328.
18. Jensen, K.E., Senterfit, L.B., Chanock, R.M., Smith, C.B., and Purcell, R.H. 1965. An inactivated Mycoplasma pneumoniae vaccine. JAMA, 194(3): 248-252. doi:10.1001/jama.1965.03090160026007.
19. Jia, F.Y., Liang, D., Fu, W.Y., Li, H.B., Lu, J.R., Chen, Y.B., and Li, C.H. 2001. Prevention of pneumonia in hamsters with Mycoplasma pneumoniae P1 protein. Chin. J. Pediatrics, 39: 293-295.
20. Jones, H.P., and Simecka, J.W. 2003. T lymphocyte responses are critical determinants in the pathogenesis and resistance to mycoplasma respiratory disease. Front. Biosci. 8: d930-d945. doi:10.2741/1098.
21. Kang, Y.M., Ding, M.J., Han, Y.L., Wang, S.F., Ma, X., and Li, H. 2011. Th1/Th2 immune response in bronchoalveolar lavage fluid in children with severe Mycoplasma pneumoniae pneumonia. Zhongguo Dang Dai Er Ke Za Zhi. 13(3): 188-190. [In Chinese.]
22. Linchevski, I., Klement, E., and Nir-Paz, R. 2009. Mycoplasma pneumoniae vaccine protective efficacy and adverse reactions - Systematic review and meta-analysis. Vaccine, 27(18): 2437-2446. doi:10.1016/j.vaccine.2009.01.135.19368785.
23. Mogabgab, W.J. 1973. Efficacy of inactivated Mycoplasma pneumoniae vaccine demonstrated by protection in large field trials. Ann. N. Y. Acad. Sci. 225: 453-461. doi:10.1111/j.1749-6632.1973.tb45669.x.
24. Mogabgab, W.J., Marchand, S., Mills, G., and Beville, R. 1975. Efficacy of inactivated Mycoplasma pneumoniae vaccine in man. Dev. Biol. Stand. 28: 597-608.
25. Morozumi, M., Iwata, S., Hasegawa, K., Chiba, N., Takayanagi, R., Matsubara, K., et al. Acute Respiratory Diseases Study Group. 2008. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community acquired pneumonia. Antimicrob. Agents Chemother. 52(1): 348-350. doi:10.1128/AAC.00779-07.
26. Nakane, D., Adan-Kubo, J., Kenri, T., and Miyata, M. 2011. Isolation and characterization of P1 adhesin, a leg protein of the gliding bacterium Mycoplasma pneumoniae. J. Bacteriol. 193(3): 715-722. doi:10.1128/JB.00796-10.
27. Ogra, P.L., Karzon, D.T., Righthand, F., and MacGillivray, M. 1968. Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. N. Engl. J. Med. 279(17): 893-900. doi:10.1056/NEJM196810242791701.
28. Pietsch, K., and Jacobs, E. 1993. Characterization of the cellular response of spleen cells in BALB/c mice inoculated with Mycoplasma pneumoniae or the P1 protein. Med. Microbiol. Immunol. (Berl.), 182(2): 77-85. doi:10.1007/BF00189375.
29. Rasmussen, J.N., Voldstedlund, M., Andersen, R.L., Ellermann-Eriksen, S., Jensen, T.G., Johansen, H.K., et al. 2010. Increased incidence of Mycoplasma pneumoniae infections detected by laboratory-based surveillance in Denmark in 2010. Euro Surveill. 15(45).
30. Schurwanz, N., Jacobs, E., and Dumke, R. 2009. Strategy to create chimeric proteins derived from functional adhesin regions of Mycoplasma pneumoniae for vaccine development. Infect. Immun. 77(11): 5007-5015. doi:10.1128/IAI.00268-09.
31. Spuesens, E.B., Oduber, M., Hoogenboezem, T., Sluijter, M., Hartwig, N.G., van Rossum, A.M., and Vink, C. 2009. Sequence variations in RepMP2/3 and RepMP4 elements reveal intragenomic homologous DNA recombination events in Mycoplasma pneumoniae. Microbiology, 155(7): 2182-2196. doi:10.1099/mic.0.028506-0.
32. Spuesens, E.B.M., Hartwig, N.G., van Rossum, A.M.C., and Vink, C. 2011. Sequence variation within the P1 gene of Mycoplasma pneumoniae. J. Clin. Microbiol. 49(10): 3723-3724. doi:10.1128/JCM.01318-11.
33. Su, C.J., Tryon, V.V., and Baseman, J.B. 1987. Cloning and sequence analysis of cytadhesin P1 gene from Mycoplasma pneumoniae. Infect. Immun. 55(12): 3023-3029.
34. Wenzel, R.P., Craven, R.B., Davies, J.A., Hendley, J.O., Hamory, B. H., and Gwaltney, J.M., Jr. 1976. Field trial of an inactivated Mycoplasma pneumoniae vaccine. I. Vaccine efficacy. J. Infect. Dis. 134(6): 571-576. doi:10.1093/infdis/134.6.571.
35. Wenzel, R.P., Craven, R.B., Davies, J.A., Hendley, J.O., Hamory, B. H., and Gwaltney, J.M., Jr. 1977. Protective efficacy of an inactivated Mycoplasma pneumoniae vaccine. J. Infect. Dis. 136 (Suppl. 1): S204-S207. doi:10.1093/infdis/136.Supplement.S204.
36. Xu, Y.C., Zhu, L.J., Xu, D., Tao, X.F., Li, S.X., Tang, L.F., and Chen, Z.M. 2011. Epidemiological characteristics and meteorological factors of childhood Mycoplasma pneumoniae pneumonia in Hangzhou. World J. Pediatr. 7(3): 240-244. doi:10.1007/s12519-011-0318-0.
37. Zhao, F., Wu, Y., Zhang, X., Yu, J., Gu, W., Liu, S., et al. 2011. Enhanced immune response and protective efficacy of a Treponema pallidum Tp92 DNA vaccine vectored by chitosan nanoparticles and adjuvanted with IL-2. Hum. Vaccin. 7(10): 1083-1089. doi:10.4161/hv.7.10.16541.
38. Zhao, F., Wang, S., Zhang, X., Gu, W., Yu, J., Liu, S., et al. 2012. Protective efficacy of a Treponema pallidum Gpd DNA vaccine vectored by chitosan nanoparticles and fused with interleukin-2. Can. J. Microbiol. 58(2): 117-123. doi:10.1139/w11-115.